Novartis Finalizes Avidity Biosciences Acquisition; Shareholders to Receive $72 Cash Per Share
Summary
Novartis has officially completed its acquisition of Avidity Biosciences, with Avidity shareholders now entitled to receive $72.00 per share in cash. This definitive action follows a series of recent developments, including the company's 10-K filing on February 23rd detailing the pending acquisition and the February 26th 8-K announcing shareholder approval of the merger and spin-off. The completion of this transaction marks the end of Avidity Biosciences as an independent publicly traded entity, triggering the final cash payout for its investors. Traders holding RNA stock should be aware of the immediate cash entitlement and the impending delisting of the shares.
At the time of this announcement, RNA was trading at $15.24 on NASDAQ in the Life Sciences sector. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.